PBPIA
TRVI icon

Pivotal bioVenture Partners Investment Advisor’s Trevi Therapeutics TRVI Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.5M Buy
1,553,726
+296,944
+24% +$3.32M 6.63% 5
2025
Q4 		$15.7M Hold
1,256,782
– – 6.08% 6
2025
Q3 		$11.5M Buy
1,256,782
+110,672
+10% +$830K 6.65% 5
2025
Q2 		$6.27M Buy
+1,146,110
New +$7.13M 3.89% 6

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's TRVI Position: Q1 2026 in Review

Pivotal bioVenture Partners Investment Advisor increased its Trevi Therapeutics (TRVI) stake by 24% in Q1 2026, buying an estimated $3.32M and bringing the position to 1,553,726 shares worth $18.5M. The position accounts for 6.63% of the portfolio, ranked #5.

Pivotal bioVenture Partners Investment Advisor first reported a position in TRVI in Q2 2025 and has held it in 4 quarters since. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Pivotal bioVenture Partners Investment Advisor held 1,553,726 shares of Trevi Therapeutics worth $18.5M as of Q1 2026.
  • Pivotal bioVenture Partners Investment Advisor bought 296,944 Trevi Therapeutics shares in Q1 2026, an estimated $3.32M.
  • Trevi Therapeutics made up 6.63% of Pivotal bioVenture Partners Investment Advisor's portfolio in Q1 2026, its #5 holding.
  • Pivotal bioVenture Partners Investment Advisor first reported a position in Trevi Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q1 2026, filed 14 May 2026.